Update Summary

Entity name

PARAGON CARE LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

11/2/2022

Reason for update to a previous announcement

This is an update to the previous Appendix 3B to reflect changes in the number of shares issued due to rounding.

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

PARAGON CARE LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ABN

76064551426

1.3 ASX issuer code

PGC

1.4 The announcement is

Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

This is an update to the previous Appendix 3B to reflect changes in the number of shares issued due to rounding.

1.4b Date of previous announcement to this update

8/2/2022

1.5 Date of this announcement

11/2/2022

1.6 The Proposed issue is:

☑ A placement or other type of issue

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

☑ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

PGC: ORDINARY FULLY PAID

Number of +securities proposed to be issued

274,178,624

Reason for the update of 'Number of +securities proposed to be issued'

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

☑ No

Please describe the consideration being provided for the +securities

The consideration for the shares the subject of the Appendix 3B (New Paragon Shares) is the acquisition by Paragon of all the fully paid ordinary shares in Quantum Health Group Limited (Quantum) pursuant to the scheme of arrangement between Quantum and its shareholders (Scheme). Quantum shareholders will be issued 0.243 New Paragon Shares for each fully paid ordinary Quantum share. The record date for determining Quantum shareholders who are eligible to receive New Paragon Shares was 7:00pm (Sydney time) on 9 February 2022.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities 105,558,770.240000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

✓ Yes

Part 7C - Timetable

7C.1 Proposed +issue date

16/2/2022

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

⊗ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
☑ No

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

⊗ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? $\ensuremath{\mathfrak{C}}$ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

© No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

✓ Yes

7D.4a Please enter the number and +class of the +securities subject to +voluntary escrow and the date from which they will cease to be subject to +voluntary escrow

125,074,672 fully paid ordinary shares issued to John Walstab (either as sole or joint holder) are subject to voluntary escrow.

50% of the escrowed securities will be released from escrow on 16 February 2023 and the remaining 50% of the escrowed securities released from escrow on 16 February 2024.

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?
⊗ No

7E.2 Is the proposed issue to be underwritten?

⊗ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Please see section 9.6 of the Quantum Scheme Booklet dated 17 December 2021.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Please see section 9.6 of the Quantum Scheme Booklet dated 17 December 2021.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? ⊗ No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a +disclosure document or +PDS for the +securities proposed to be issued